PMID- 33364086
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Nov 18
TI  - Excellent Outcome of Protocol-Based Treatment of Motivated Type 2 Diabetes 
      Mellitus (T2DM) Patients: A Real World Follow-Up for 11 Years.
PG  - e11558
LID - 10.7759/cureus.11558 [doi]
LID - e11558
AB  - Introduction and aim To evaluate the real-world clinical outcome of 
      guideline-based treatment among adherent and committed type 2 diabetes mellitus 
      (T2DM) patients. Methods The study reports the outcomes of an 11-year 
      clinic-based standard care regime, based on the American Diabetes Association 
      (ADA) guidelines and implemented in the authors' practices. Records of 145 T2DM 
      patients, who were regularly followed up, were reviewed. Descriptive and 
      inferential statistical analysis was carried out with the Statistical Analysis 
      System (SAS) (SAS Institute Inc., Cary, NC, USA) and with Statistical Package for 
      Social Sciences (SPSS) (IBM Corp., Armonk, NY, USA), with Microsoft Word and 
      Excel to generate graphs and tables. Results Apart from a significant increase of 
      body weight (but not of body mass index, BMI) and a significant decrease of 
      diastolic blood pressure (DBP), there were insignificant changes in all major 
      biochemical parameters, fasting plasma glucose (FPG), postprandial plasma glucose 
      (PPG), glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), 
      creatinine, estimated glomerular filtration rate (eGFR) and urine albumin 
      creatinine ratio (ACR), over the 11 years of follow-up. Conclusion ADA 
      guideline-based management effectively maintained treatment goals among treatment 
      adherent and committed T2DM patients over 11 years. Glycemic parameters (FPG, 
      PPG, and HbA1c) and renal parameters (serum creatinine, eGFR, and ACR levels) 
      remained stable. Our outcomes data were better than those recorded in the 
      landmark United Kingdom Prospective Diabetes Study (UKPDS) and Action in Diabetes 
      and Vascular Disease: Preterax and Diamicron Modified Release Controlled 
      Evaluation (ADVANCE).
CI  - Copyright (c) 2020, Chatterjee et al.
FAU - Chatterjee, Sudip
AU  - Chatterjee S
AD  - Endocrinology, Vivekananda Institute of Medical Sciences, Kolkata, IND.
FAU - Majumder, Anirban
AU  - Majumder A
AD  - Endocrinology, Kali Prasad Chowdhury Medical College & Hospital, Kolkata, IND.
LA  - eng
PT  - Journal Article
DEP - 20201118
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7749796
OTO - NOTNLM
OT  - ada guidelines
OT  - long term follow up
OT  - outcome
OT  - real world
OT  - t2dm
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
PMCR- 2020/11/18
CRDT- 2020/12/28 12:01
PHST- 2020/12/28 12:01 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
PHST- 2020/11/18 00:00 [pmc-release]
AID - 10.7759/cureus.11558 [doi]
PST - epublish
SO  - Cureus. 2020 Nov 18;12(11):e11558. doi: 10.7759/cureus.11558.